Intercept Pharmaceuticals (ICPT): doc panel post-REGENERATE supports 'significant uptake' - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating and $191.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
